Join the Ozempic group to help and get support from people like you.
Ozempic News (Page 4)
Perioperative GLP-1 RA Use Reduces Risk for Complications in Patients With Diabetes
MONDAY, Jan. 13, 2025 – For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with...
Semaglutide Doubles Risk for Nonarteritic Anterior Ischemic Optic Neuropathy
TUESDAY, Jan. 14, 2025 – Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a...
Can Elderberry Juice Help You Lose Weight?
FRIDAY, Jan. 10, 2025 – Ozempic? Wegovy? Zepbound? How about elderberry juice? Elderberry juice might help people lose weight and improve their blood sugar control, a new small-scale study says....
Some GLP-1s Achieve More Weight Loss Than Others: Study
WEDNESDAY, Jan. 8, 2025 – Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been approved for that purpose. A new evidence review published ...
GLP-1 RAs Efficacious for Weight Loss in Overweight, Obesity Without Diabetes
TUESDAY, Jan. 7, 2025 – For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published...
How do GLP-1s Boost Weight Loss, Heart Health?
THURSDAY, Jan. 2, 2024 – Weight loss tops many folks’ list of New Years resolutions, and lots of people are turning to cutting-edge weight-loss drugs like Ozempic to help them drop excess pounds. T...
Weight-Loss Drugs, Wily Viruses, Abortion Pill Under Attack: The Top Health Stories of 2024
MONDAY, Dec. 30, 2024 – It was a year in health news that will be hard to forget. As blockbuster weight-loss drugs known as GLP-1s made a sizable dent in the obesity epidemic, study after study...
GLP-1 RAs Reduce Risk for Clinically Important Kidney, CVD Outcomes
FRIDAY, Dec. 6, 2024 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascular disease outcomes in individuals with type 2 diabetes,...
New Weight-Loss Advance: A Gastric Balloon You Control to Feel Full or Not
TUESDAY, Dec. 3, 2024 – GLP-1 meds are all the rage for weight loss nowadays, but not everyone can safely take the drugs to shed pounds. Invasive weight-loss surgeries can often be a tough sell,...
American Heart Association, Nov. 16-18
The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from around the world, including cardiovascular specialists, surgeons, and n...
Biden Seeks Coverage for GLP-1 RA Medications by Medicare, Medicaid
TUESDAY, Nov. 26, 2024 – The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy)...
Study Finds GLP-1 Meds, such as Ozempic, Wegovy, Can Also Help the Kidneys
TUESDAY, Nov. 26, 2024 – The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm. In the largest study to...
Biden Will Move to Have Medicare, Medicaid Cover GLP-1 Weight-Loss Meds, such as Wegovy, Zepbound
TUESDAY, Nov. 26, 2024 – The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and...
Stroke Guidelines Updated, With Focus on Women and GLP-1s
MONDAY, Nov. 25, 2024 – Women, especially those who had high blood pressure during pregnancy or entered menopause before age 45, are among those with a greater risk for stroke. They and other...
Taking a GLP-1 Medication? Here's Tips to Holiday Eating
SATURDAY, Nov. 23, 2024 – So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle gatherings where...
Further information
Related condition support groups
Cardiovascular Risk Reduction, Chronic Kidney Disease, Diabetes, Type 2